Article
KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation.
The Cochrane database of systematic reviews - 17 Feb 2026
Noordhof Anneloes, Asmara Oke Dimas, de Jong Kim, Gijtenbeek Rolof Gp, Huitema Ymkje Ma, van Vollenhoven Femke Hm, Venmans Ben Jw, Hendriks Lizza, van Geffen Wouter H
Abstract excerpt
OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of G12C-inhibitors compared to chemotherapy in second line and beyond in adults with advanced/metastatic non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma (KRAS) G12C mutation.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.